Loading
Toremifene (Fareston) is a tamoxifen-like tablet for postmenopausal women with hormone-sensitive breast cancer that has spread.
Toremifene was approved by the FDA in May 1997 for metastatic breast cancer in postmenopausal women with oestrogen receptor-positive or unknown tumours, on three randomised trials (North American, Eastern European and Nordic) that showed response rates and time to progression similar to tamoxifen; the EU authorised Fareston in 1996 for first-line hormonal treatment of hormone-dependent metastatic breast cancer. It never displaced tamoxifen and aromatase inhibitors then moved ahead of both. QT prolongation carries a boxed warning; hot flushes, sweating and vaginal discharge are the common effects, with thromboembolism and endometrial changes as class risks.
Chlorinated tamoxifen analogue that binds the oestrogen receptor and acts as an antagonist in breast tissue with partial agonist effects elsewhere. Connects to Estrogen receptor (ERα).
1.Toremifene acts on Estrogen receptor (ERα), the hormone receptor or the enzyme that makes the hormone.
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Compare all products across the US, EU, UK, Japan, China and Australia →
| Region | Year | Indication |
|---|---|---|
| US | 1997 | Metastatic breast cancer in postmenopausal women with ER-positive or unknown tumours |
| EU | 1996 | First-line hormonal treatment of hormone-dependent metastatic breast cancer in postmenopausal women |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Toremifene" OR ABSTRACT:"Toremifene" OR TITLE:"Fareston" OR ABSTRACT:"Fareston") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Toremifene, not a curated reading list.
Shares Tamoxifen, Estrogen receptor (ERα), Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
Shares Tamoxifen, Estrogen receptor (ERα), Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
Shares Tamoxifen, Estrogen receptor (ERα), Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
Shares Estrogen receptor (ERα), Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
Shares Estrogen receptor (ERα), Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
Shares Tamoxifen, Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
Shares Estrogen receptor (ERα), Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
Shares Tamoxifen, Estrogen receptor (ERα), Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.